Scarica l'app Stockscreener
21.02
0.09%
-0.07
Precedente Chiudi:
$21.09
Aprire:
$21.2
Volume 24 ore:
65,417
Relative Volume:
2.35
Capitalizzazione di mercato:
$919.97M
Reddito:
-
Utile/perdita netta:
$-75.28M
Rapporto P/E:
-10.53
EPS:
-1.9957
Flusso di cassa netto:
$-57.45M
1 W Prestazione:
+13.55%
1M Prestazione:
+21.09%
6M Prestazione:
+25.79%
1 anno Prestazione:
+41.50%
Intervallo 1D:
$20.92
$21.40
Intervallo di 1 settimana:
$18.52
$21.94
Portata 52W:
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Nome
Oculis Holding Ag
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OCS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
21.07 | 1.10B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.80 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.35 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.78 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-27 | Iniziato | Needham | Buy |
| 2023-12-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-10-05 | Iniziato | Stifel | Buy |
| 2023-06-14 | Iniziato | BofA Securities | Buy |
| 2023-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2023-06-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-10 | Iniziato | Pareto | Buy |
| 2023-04-28 | Iniziato | Wedbush | Outperform |
Mostra tutto
Oculis Holding Ag Borsa (OCS) Ultime notizie
Live market analysis of Oculis Holding AG Equity WarrantJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com
Oculis Holding AG Equity Warrant’s volatility index tracking explainedWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
Why Oculis Holding AG Equity Warrant stock could outperform in 2025Profit Target & AI Based Trade Execution Alerts - newser.com
Leading vs lagging indicators on Oculis Holding AG performanceEarnings Risk Report & Precise Trade Entry Recommendations - newser.com
What’s the recovery path for long term holders of Oculis Holding AGJuly 2025 Earnings & Reliable Trade Execution Plans - newser.com
Will Oculis Holding AG stock gain from strong economyQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Using data tools to time your Oculis Holding AG Equity Warrant exitJuly 2025 PostEarnings & Weekly High Return Opportunities - newser.com
Chardan Capital Issues Positive Estimate for Oculis Earnings - MarketBeat
Risk adjusted return profile for Oculis Holding AG analyzedPrice Action & Low Drawdown Momentum Ideas - newser.com
Using RSI to spot recovery in Oculis Holding AG Equity Warrant2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Will Oculis Holding AG Equity Warrant price bounce be sustainableJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Sentiment analysis tools applied to Oculis Holding AGMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Why Oculis Holding AG (CR5) stock is favored by hedge fundsIPO Watch & Long-Term Capital Growth Strategies - newser.com
Chart based analysis of Oculis Holding AG trendsJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock? - Nasdaq
Oculis' (OCS) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Is Oculis Holding AG Equity Warrant stock entering bullish territoryJuly 2025 Drop Watch & Verified Technical Trade Signals - newser.com
Price action breakdown for Oculis Holding AG Equity WarrantEarnings Recap Summary & Consistent Return Investment Signals - newser.com
Will Oculis Holding AG (CR5) stock benefit from sector leadershipIPO Watch & Accurate Technical Buy Alerts - newser.com
Chardan Capital Forecasts Strong Price Appreciation for Oculis (NASDAQ:OCS) Stock - Defense World
Oculis Holding AG Equity Warrant stock momentum explainedFed Meeting & Daily Growth Stock Tips - newser.com
What recovery options are there for Oculis Holding AG Equity Warrant - newser.com
What to expect from Oculis Holding AG in the next 30 daysTrade Signal Summary & Smart Swing Trading Alerts - newser.com
Can volume confirm reversal in Oculis Holding AG2025 Price Momentum & Reliable Trade Execution Plans - newser.com
Applying chart zones and confluence areas to Oculis Holding AG Equity Warrant2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Oculis (NASDAQ:OCS) Sees Large Volume Increase Following Analyst Upgrade - Defense World
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Chardan Research Adjusts Oculis Holding AG Price Target to $51 From $33, Maintains Buy Rating - MarketScreener
Oculis (NASDAQ:OCS) Price Target Raised to $51.00 - MarketBeat
Chardan Capital Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price - Defense World
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
Oculis (NASDAQ:OCS) Given New $36.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Oculis stock price target raised to $36 from $33 at H.C. Wainwright - Investing.com
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION - Ophthalmology Times
Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology - TipRanks
Does Oculis Holding AG Equity Warrant show high probability of reboundJuly 2025 Rallies & Community Supported Trade Ideas - newser.com
Reversal indicators forming on Oculis Holding AG Equity Warrant stockEarnings Risk Summary & Weekly High Conviction Trade Ideas - newser.com
Oculis Advances Privosegtor Into Registrational Trials for Neuroprotective Therapy - MarketScreener
Will Oculis Holding AG Equity Warrant bounce back from current supportJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Why retail traders accumulate Oculis Holding AG (CR5) stockJuly 2025 Review & Weekly Breakout Watchlists - newser.com
Can trapped investors hope for a rebound in Oculis Holding AG Equity WarrantJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy - The Manila Times
Oculis Advances Privosegtor into Pivotal Development for Acute Optic Neuritis and NAION Following Positive FDA Meeting - Quiver Quantitative
Will Oculis Holding AG (CR5) stock sustain bullish trend into 2025Trade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
3 pivotal trials: Oculis launches PIONEER program for Privosegtor after positive FDA meeting - Stock Titan
Brokerages Set Oculis Holding AG (NASDAQ:OCS) PT at $35.75 - Defense World
What machine learning models say about Oculis Holding AG2025 Top Gainers & Free High Return Stock Watch Alerts - newser.com
Published on: 2025-10-05 06:40:04 - newser.com
Published on: 2025-10-05 05:35:30 - newser.com
Oculis Holding Ag Azioni (OCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):